The Role of Checkpoint inhibitors in CIA

检查点抑制剂在 CIA 中的作用

基本信息

  • 批准号:
    10319910
  • 负责人:
  • 金额:
    $ 4.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Abstract Immune related adverse events linked to severe inflammatory arthritis have been identified in 10-43% of patients receiving immune checkpoint inhibitors, αCTLA4, αPD-1 or αPD-L1, indicating the importance of immune inhibitory pathways in maintaining homeostasis in the joints. We obtained human synovial fluid and found a high frequency of PD-L1 expression by synovial macrophages. We propose to examine the role of PD-L1 expression in synovial macrophages and T cells during murine collagen induced arthritis (CIA). We found that immune checkpoint inhibitor, PD-L1, is primarily expressed in the joint compared to other immune checkpoints. Additionally, we found synovial macrophages and CD3+ T cells are the main PD-L1 expressing cells in the joint, and PD-L1 expression is increased during CIA. We extensively profiled the synovial macrophages and found three populations of PD-L1 expressing cells: F4/80intCD115+CCR2-MHCII-CD73-Tim4-PD-L1hi (CD115+ macrophages), F4/80hiCD115-CCR2intMHCIIhiCD73intTim4intPD-L1int (MHCII+ macrophages), and F4/80intCD115- CCR2lowMHCII-CD73loTim4intPD-L1int (F4/80+ macrophages). We have also found that PD-L1 has the highest frequency of expression in CD4+ and CD8+ T cells. Furthermore, we identified a novel subset of joint tissue resident memory T cells in the naïve joint that are phenotypically CD8+CD69+ and CD8+CD69+CD103+. We hypothesize that the expression of PD-L1 by macrophages and/or T cells are essential for synovial homeostasis and regulation of joint inflammation. In Aim 1, we will examine the importance of PD-L1 expression by synovial macrophages through the selective deletion of PD-L1 using the cre/flox system. We will generate two macrophages specific PD-L1 KO mice, LyzcrePD-L1fl/fl and CD115crePD-L1fl/fl. We will induce CIA in LyzcrePD-L1fl/fl, CD115crePD-L1fl/fl, Lyzcre and CD115cre mice and harvest the joint to determine the protective role of synovial macrophage PD-L1 expression in CIA (Subaim 1.1). We will also perform parabiosis experiments by surgically joining CD45.1 C57BL6 and CD45.2 CD115crePD-L1fl/fl to determine if PD-L1+ synovial macrophages are resident or bone marrow derived during CIA (Subaim 1.2). We have found that PD-L1 is highly expressed in synovial T cells. In Aim 2, we will examine the protective function of synovial T cells following CIA. We will use LckcreP D-L1fl/fl mice, which lack PD-L1 expression in CD3+ T cells to examine the effects of PD-L1 specific deletion in T cells during CIA (Subaim 2.1). To test if tissue resident memory T cells play a protective role during CIA, we will utilize a tissue resident chimera mouse model to selectively delete peripheral T cells in LckcrePD- L1fl/fl mice. Donor T cells from LckcrePD-L1fl/fl or Lckcre mice will replace peripheral T cell populations to confirm the protective function of tissue resident memory T cells in the joint (Subaim 2.2). Our project has high translational potential since joint specific PD-L1 expression could be modulated with therapeutic purposes in humans for rheumatoid arthritis or check point inhibitors induced arthritis.
摘要 在10%-43%的患者中发现了与严重炎症性关节炎有关的免疫相关不良事件 接受免疫检查点抑制剂,αCTLA4,αPD-1或αPD-L1,表明免疫的重要性 维持关节内动态平衡的抑制途径。我们提取了人体滑液,发现高密度 滑膜巨噬细胞表达PD-L1的频率。我们建议研究PD-L1表达的作用 在小鼠胶原性关节炎(CIA)过程中滑膜巨噬细胞和T细胞的表达。我们发现这种免疫力 与其他免疫检查点相比,检查点抑制因子PD-L1主要在关节中表达。 此外,我们还发现滑膜巨噬细胞和CD3+T细胞是关节中表达PD-L1的主要细胞, 在CIA过程中,PD-L1的表达增加。我们对滑膜巨噬细胞进行了广泛的分析,发现 三种PD-L1表达细胞:F4/80intCD115+CCR2-MHCII-CD73-Tim4-PD-L1hi(CD115+ 巨噬细胞)、F4/80hiCD115-CCR2intMHCIIhiCD73intTim4intPD-L1int(巨噬细胞)和F4/80intCD115- CCR2lowMHCII-CD73loTim4intPD-L1int(F4/80+巨噬细胞)。我们还发现PD-L1具有最高的 在CD4+和CD8+T细胞中的表达频率。此外,我们还鉴定了一个新的关节组织亚群。 幼稚关节内的常驻记忆T细胞,表型为CD8+CD69+和CD8+CD69+CD103+。我们 假设巨噬细胞和/或T细胞表达PD-L1对滑膜是必需的 关节炎症的动态平衡和调节。在目标1中,我们将检查PD-L1的重要性 滑膜巨噬细胞通过使用cre/flx系统选择性删除PD-L1表达。我们会 建立巨噬细胞特异性PD-L1KO小鼠LyzcrePD-L1fl/fl和CD115crePD-L1fl/fl。我们会诱使中情局 LyzcrePD-L1fl/fl、CD115crePD-L1fl/fl、Lyzcre和CD115cre小鼠,观察其对关节的保护作用 CIA滑膜巨噬细胞PD-L1的表达(Subaim 1.1)。我们还将通过以下方式进行异种繁殖实验 CD45.1 C57BL6和CD45.2 CD115crePD-L1fl/fl联合检测PD-L1+滑膜巨噬细胞 是中情局期间的常驻或骨髓来源(Subaim 1.2)。我们发现PD-L1高表达 在滑膜T细胞中。在目标2中,我们将研究CIA后滑膜T细胞的保护功能。我们将使用 Lockcrep D-L1fl/fl小鼠,在CD3+T细胞中缺乏PD-L1表达,以检测PD-L1特异性的影响 CIA期间T细胞的缺失(Subaim 2.1)。为了测试组织驻留记忆T细胞是否在 CIA,我们将利用组织驻留嵌合体小鼠模型选择性地删除LockcrePD- L1fl/fl小鼠。来自LockcrePD-L1fl/fl或Lockcre小鼠的供体T细胞将取代外周T细胞群以证实 关节中组织驻留记忆T细胞的保护功能(Subaim 2.2)。我们的项目有很高的 由于关节特异性PD-L1的表达可以根据治疗目的进行调节,因此具有翻译潜力 人类用于类风湿性关节炎或检查点抑制剂引起的关节炎。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Megan Kay Wood其他文献

Megan Kay Wood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Megan Kay Wood', 18)}}的其他基金

The Role of Checkpoint inhibitors in CIA
检查点抑制剂在 CIA 中的作用
  • 批准号:
    10437927
  • 财政年份:
    2020
  • 资助金额:
    $ 4.6万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.6万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.6万
  • 项目类别:
    Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
  • 批准号:
    10068495
  • 财政年份:
    2024
  • 资助金额:
    $ 4.6万
  • 项目类别:
    Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 4.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
  • 批准号:
    24K19850
  • 财政年份:
    2024
  • 资助金额:
    $ 4.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 4.6万
  • 项目类别:
    Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
  • 批准号:
    489316
  • 财政年份:
    2023
  • 资助金额:
    $ 4.6万
  • 项目类别:
    Operating Grants
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
  • 批准号:
    23K14987
  • 财政年份:
    2023
  • 资助金额:
    $ 4.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 4.6万
  • 项目类别:
    Fellowship
The roles and mechanisms of inflammation resolution in the development of Rheumatoid Arthritis
炎症消退在类风湿关节炎发展中的作用和机制
  • 批准号:
    10733789
  • 财政年份:
    2023
  • 资助金额:
    $ 4.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了